About the Company
dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ALDX News
Aldeyra Therapeutics Inc President and CEO Todd Brady Sells Company Shares
Todd Brady, President and CEO of Aldeyra Therapeutics Inc (NASDAQ:ALDX), has sold 183,238 shares of the company on March 12, ...
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
The company has a Zacks Rank #2 (Buy). Aldeyra Therapeutics, Inc. price-consensus-chart | Aldeyra Therapeutics, Inc. Quote Some other top-ranked drug/biotech companies worth considering are ...
Aldeyra Therapeutics Inc ALDX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Strong Buy Rating for Aldeyra Therapeutics Backed by Reproxalap Developments and Strategic Partnerships
Thomas Shrader, an analyst from BTIG, maintained the Buy rating on Aldeyra Therapeutics (ALDX – Research Report). The associated price ...
Institutions own 37% of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares but retail investors control 37% of the company
We can report that insiders do own shares in Aldeyra Therapeutics, Inc.. It has a market capitalization of just US$202m, and insiders have US$4.8m worth of shares, in their own names. Some would say ...
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
Burlington, MA-based Aldeyra Therapeutics ALDX is a leader in the development of RASP (reactive aldehyde species) modulators for the treatment of immune-mediated diseases. Lately, it has seen success ...
Aldeyra Therapeutics Inc ALDX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...